Osaka International Cancer Institute Launches New Prostate Cancer Treatment: "Radiopharmaceutical Ligand Therapy"

Q: What are the key facts in this article?

Osaka International Cancer Institute has launched "PSMA Radioactive Ligand Therapy," a new treatment targeting substances found in prostate cancer cells. This advanced therapy expands treatment options and provides optimal, personalized care for prostate cancer patients.

Q: What is the direct answer?

Osaka International Cancer Institute has launched "PSMA Radioactive Ligand Therapy," a new treatment targeting substances found in prostate cancer cells. This advanced therapy expands treatment options and provides optimal, personalized care for prostate cancer patients.

Q: What is the source and date?

Source: https://prtimes.jp/main/html/rd/p/000000004.000179627.html | Date: Date unavailable

The Osaka International Cancer Institute (Location: Chuo-ku, Osaka City, Director-General: Nariaki Matsuura), a local independent administrative agency of the Osaka Prefectural Hospital Organization, is pleased to announce the launch of "PSMA Radioactive Ligand Therapy," which targets substances found in prostate cancer cells. PSMA (Prostate-Specific Membrane Antigen) is a protein commonly found in prostate cancer cells. In recent years, the diagnosis and treatment of prostate cancer targeting this PSMA have attracted significant attention and great expectations both in Japan and internationally. At the Osaka International Cancer Institute, the Urology Department, Isotope Therapy Department, Nursing Department, Medical Technology Department (Radiology Division), and Administrative Office have collaborated to newly introduce PSMA-targeted treatment for eligible prostate cancer cases. This will broaden the treatment options for prostate cancer patients and enable the provision of optimal treatment tailored to each patient's condition. [Comment] Norihiko Kawamura, Deputy Director of Urology: "Treatment for prostate cancer is advancing year by year, and it is crucial to select appropriate treatment according to the patient's condition. The introduction of PSMA radioactive ligand therapy at our center will expand the range of treatments we can offer, and we expect it to lead to the realization of personalized treatment for each patient." [Related Treatments] In addition to this, the Osaka International Cancer Institute is engaged in treatments using radiopharmaceuticals. For neuroendocrine tumors, peptide receptor radionuclide therapy is performed in dedicated hospital rooms for safety management. Please refer to the following page for details: https://oici.jp/hospital/department/rarecancer/ [Reference] Dedicated Hospital Room (Image: may differ from actual layout) For this treatment, special radiopharmaceuticals are used, so considering the impact on the surroundings, t

Osaka International Cancer Institute Launches New Prostate Cancer Treatment: "Radiopharmaceutical Ligand Therapy"

AI Summary (NQ-processed)

AI Analysis